Is Fluorescent Cystoscopy of Cost/Benefit/Therapeutic Value for Carcinoma In Situ of the Bladder? NO (a difficult task)

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › peer-review

3 Citations (Scopus)

Keywords

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{9506843238274bceafcac39189bf880f,

title = "Is Fluorescent Cystoscopy of Cost/Benefit/Therapeutic Value for Carcinoma In Situ of the Bladder? NO (a difficult task)",

keywords = "MITOMYCIN, CANCER",

author = "Timothy O'Brien",

year = "2013",

month = jul,

doi = "10.1016/j.juro.2013.04.039",

language = "English",

volume = "190",

pages = "20--21",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Is Fluorescent Cystoscopy of Cost/Benefit/Therapeutic Value for Carcinoma In Situ of the Bladder? NO (a difficult task)

AU - O'Brien, Timothy

PY - 2013/7

Y1 - 2013/7

KW - MITOMYCIN

KW - CANCER

U2 - 10.1016/j.juro.2013.04.039

DO - 10.1016/j.juro.2013.04.039

M3 - Editorial

SN - 0022-5347

VL - 190

SP - 20

EP - 21

JO - Journal of Urology

JF - Journal of Urology

IS - 1

ER -